• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    2/14/22 3:00:55 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MRNA alert in real time by email
    SC 13G/A 1 d206773dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Moderna, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    60770K 10 7

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 60770K 10 7    13G/A    Page  2  of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship VentureLabs IV, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      11,460,435

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      11,460,435

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      11,460,435

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      2.8%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO


    CUSIP No. 60770K 10 7    13G/A    Page  3  of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship Ventures Fund IV, LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      14,736,774

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      14,736,774

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      14,736,774

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      3.6%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN


    CUSIP No. 60770K 10 7    13G/A    Page  4  of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship Ventures Fund IV-Rx, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      2,840,318

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      2,840,318

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,840,318

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      0.7%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN


    CUSIP No. 60770K 10 7    13G/A    Page  5  of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship Ventures Fund IV General Partner LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      17,577,092

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      17,577,092

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      17,577,092

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      4.3%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO


    CUSIP No. 60770K 10 7    13G/A    Page  6  of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Flagship Pioneering, Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      37,040 (1)

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      37,040 (1)

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      37,040 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      Less than 0.1%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO

     

    (1)

    Includes options to purchase 33,116 shares of Common Stock that are exercisable within 60 days of December 31, 2021.


    CUSIP No. 60770K 10 7    13G/A    Page  7  of 13 Pages

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Noubar B. Afeyan, Ph.D.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      2,394,408 (1)

       6  

      SHARED VOTING POWER

     

      17,614,132 (2)

       7  

      SOLE DISPOSITIVE POWER

     

      2,394,408 (1)

       8  

      SHARED DISPOSITIVE POWER

     

      17,614,132 (2)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      20,008,540 (1)(2)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      4.9%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

     

    (1)

    Includes (i) 2,238,970 shares of Common Stock held directly by Dr. Afeyan and (ii) options to purchase 155,438 shares of Common Stock that are exercisable within 60 days of December 31, 2021.

    (2)

    Includes options to purchase 33,116 shares of Common Stock held directly by Flagship Pioneering, Inc. that are exercisable within 60 days of December 31, 2021.


    CUSIP No. 60770K 10 7    13G/A    Page  8  of 13 Pages

     

    Item 1(a).Name of Issuer:

    Moderna, Inc. (the “Issuer”)

    Item 1(b).Address of Issuer’s Principal Executive Offices:

    200 Technology Square

    Cambridge, MA 02139

    Item 2(a).Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Flagship VentureLabs IV, LLC (“VentureLabs IV”)

    Flagship Ventures Fund IV, L.P. (“Flagship IV Fund”)

    Flagship Ventures Fund IV-Rx, L.P. (“Flagship IV-Rx Fund”)

    Flagship Ventures Fund IV General Partner LLC (“Flagship IV GP”)

    Flagship Pioneering, Inc. (“Flagship Pioneering”)

    Noubar B. Afeyan, Ph.D. (“Dr. Afeyan”)

    Item 2(b).Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    c/o Flagship Pioneering Inc.

    55 Cambridge Parkway, Suite 800E

    Cambridge, Massachusetts 02142

    Item 2(c).Citizenship:

     

    VentureLabs IV    Delaware
    Flagship IV Fund    Delaware
    Flagship IV-Rx Fund    Delaware
    Flagship IV GP    Delaware
    Flagship Pioneering    Delaware
    Dr. Afeyan    United States of America

    Item 2(d).Title of Class of Securities:

    Common Stock, $0.0001 par value per share (“Common Stock”).

    Item 2(e).CUSIP Number:

    60770K 10 7

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    CUSIP No. 60770K 10 7    13G/A    Page  9  of 13 Pages

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 405,449,527 shares of outstanding Common Stock, as reported in the Issuer’s report on Form 10-Q filed with the Securities and Exchange Commission on October 29, 2021.

    Flagship IV Fund is the manager of VentureLabs IV and, as such, may be deemed to beneficially own the shares held by VentureLabs.

    Flagship IV GP is the general partner of each of Flagship IV Fund and Flagship IV-Rx Fund, and, as such, may be deemed to beneficially own the shares beneficially owned by Flagship IV Fund and Flagship IV-Rx Fund.

    Dr. Afeyan is the manager of Flagship IV GP and, as such, may be deemed to beneficially own shares beneficially owned by Flagship IV GP.

    Dr. Afeyan is the Chief Executive Officer, sole stockholder and director of Flagship Pioneering and, as such, may be deemed to beneficially own shares beneficially owned by Flagship Pioneering.

    Each of the Reporting Persons expressly disclaims beneficial ownership of the shares reported in this Schedule 13G except to the extent of its or his pecuniary interest in such shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following X.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the SubsidiaryWhich Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.

    Material Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13G.


    CUSIP No. 60770K 10 7    13G/A    Page  10  of 13 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2022

     

    FLAGSHIP VENTURES FUND IV, L.P.
    By:  

    Flagship Ventures Fund IV General

    Partner LLC

      General Partner
      By:  

    /s/ Noubar B. Afeyan, Ph.D.

        Noubar B. Afeyan, Ph.D.
        Manager
    FLAGSHIP VENTURES FUND IV-Rx, L.P.
    By:  

    Flagship Ventures Fund IV General

    Partner LLC

      General Partner
      By:  

    /s/ Noubar B. Afeyan, Ph.D.

        Noubar B. Afeyan, Ph.D.
        Manager
    FLAGSHIP PIONEERING, INC.
      By:  

    /s/ Noubar B. Afeyan, Ph.D.

        Noubar B. Afeyan, Ph.D.
        CEO, Sole Stockholder & Director
    FLAGSHIP VENTURELABS IV, LLC
    By:   Flagship Ventures Fund IV, L.P.
      Manager
      By: Flagship Ventures Fund IV General Partner LLC
      General Partner
      By:  

    /s/ Noubar B. Afeyan, Ph.D.

        Noubar B. Afeyan, Ph.D.
        Manager


    CUSIP No. 60770K 10 7    13G/A    Page  11  of 13 Pages

     

    FLAGSHIP VENTURES FUND IV

    GENERAL PARTNER LLC

    By:

     

    /s/ Noubar B. Afeyan, Ph.D.

      Noubar B. Afeyan, Ph.D.
      Manager

     

    /s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.


    CUSIP No. 60770K 10 7    13G/A    Page  1 2 of 13 Pages

     

    EXHIBIT 1

    AGREEMENT

    The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

    Date: February 14, 2022

     

    FLAGSHIP VENTURES FUND IV, L.P.
    By:   Flagship Ventures Fund IV General Partner LLC
      General Partner
      By:  

    /s/ Noubar B. Afeyan, Ph.D.

        Noubar B. Afeyan, Ph.D.
        Manager
    FLAGSHIP VENTURES FUND IV-Rx, L.P.
    By:   Flagship Ventures Fund IV General Partner LLC
      General Partner
      By:  

    /s/ Noubar B. Afeyan, Ph.D.

        Noubar B. Afeyan, Ph.D.
        Manager
    FLAGSHIP PIONEERING, INC.
      By:  

    /s/ Noubar B. Afeyan, Ph.D.

        Noubar B. Afeyan, Ph.D.
        CEO, Sole Stockholder & Director
    FLAGSHIP VENTURELABS IV, LLC
    By:   Flagship Ventures Fund IV, L.P.
      Manager
      By: Flagship Ventures Fund IV General Partner LLC
      General Partner
      By:  

    /s/ Noubar B. Afeyan, Ph.D.

        Noubar B. Afeyan, Ph.D.
        Manager


    CUSIP No. 60770K 10 7    13G/A    Page 13 of 13 Pages

     

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC
        By:  

    /s/ Noubar B. Afeyan, Ph.D.

      Noubar B. Afeyan, Ph.D.
      Manager

     

    /s/ Noubar B. Afeyan, Ph.D.

    Noubar B. Afeyan, Ph.D.

    Get the next $MRNA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MRNA

    DatePrice TargetRatingAnalyst
    3/13/2025$40.00Neutral
    Citigroup
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    1/29/2025$99.00 → $51.00Buy → Neutral
    Goldman
    12/18/2024Buy → Hold
    Argus
    12/10/2024$41.00Underperform
    BofA Securities
    11/19/2024$42.00Hold
    Berenberg
    11/18/2024$58.00Hold → Buy
    HSBC Securities
    11/15/2024$40.00Underperform
    Wolfe Research
    More analyst ratings

    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

      Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod

      7/1/25 6:30:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $MRNA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Moderna Inc.

      SCHEDULE 13G - Moderna, Inc. (0001682852) (Subject)

      5/12/25 10:36:17 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Moderna, Inc. (0001682852) (Filer)

      5/5/25 4:03:04 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Moderna Inc.

      10-Q - Moderna, Inc. (0001682852) (Filer)

      5/1/25 4:02:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mock James M converted options into 1,453 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 5% to 16,941 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      7/7/25 4:59:55 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Hussain Abbas sold $8,736 worth of shares (312 units at $28.00), decreasing direct ownership by 35% to 580 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      6/12/25 4:22:39 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer Klinger Shannon Thyme converted options into 1,139 shares and covered exercise/tax liability with 551 shares, increasing direct ownership by 2% to 27,483 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      6/9/25 4:20:30 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Moderna with a new price target

      Citigroup initiated coverage of Moderna with a rating of Neutral and set a new price target of $40.00

      3/13/25 8:15:14 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna downgraded by Barclays with a new price target

      Barclays downgraded Moderna from Overweight to Equal Weight and set a new price target of $45.00 from $111.00 previously

      2/18/25 7:11:52 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna downgraded by Goldman with a new price target

      Goldman downgraded Moderna from Buy to Neutral and set a new price target of $51.00 from $99.00 previously

      1/29/25 7:08:27 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health

      Owen joins to lead new phase of growth for the medical device company in clinical trial, diagnostic, and reference laboratory applications CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and YourBio Health, a pioneer in remote blood collection technology, today announced the appointment of Paul Owen as Chief Executive Officer of YourBio Health and CEO-Partner of Flagship Pioneering. Owen joins YourBio Health and Flagship after a corporate leadership and strategic planning career spanning more than 35 years. He was most r

      2/19/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      4/10/24 2:03:52 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      2/7/24 8:42:56 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      1/29/24 3:26:24 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Financials

    Live finance-specific insights

    See more
    • Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

      Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnounces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024."During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I

      11/7/24 6:30:00 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

      CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the adv

      10/17/24 7:05:00 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates

      Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billionReceived U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in JuneAnnounced positive Phase 3 data for combination vaccine against influenza and COVID-19Announced positive Phase 3 data for next-generation COVID-19 vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024."During the second quarter, we marked the approval of our

      8/1/24 6:30:00 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care